Five epileptic women needing to commence phenytoin therapy during pregnancy received a single intravenous and a single oral dose of phenytoin several days apart before starting regular intake of the drug. Plasma phenytoin concentration — time data were analysed by three different pharmacokinetic techniques. However assessed, the mean oral bioavailability of the drug proved to be about 90% of the intravenous bioavailability. This finding makes it unlikely that impaired bioavailability accounts for the increase in oral phenytoin dosage necessary in pregnancy to maintain plasma phenytoin concentrations at pre-pregnancy values. Phenytoin clearance in the pregnant subjects was approximately double the published values for phenytoin clearance in nonpregnant persons. This suggests that increased (metabolic) clearance accounts for the increased phenytoin dosage requirement of pregnancy.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Cranford RE, Leppik IE, Patrick B, Anderson CB, Kostick B (1977) Intravenous phenytoin: clinical and pharmacokinetic aspects. Neurology (Minneapolis) 27: 376
Dam M, Mygind K, Christiansen J (1976) Antiepileptic drugs, plasma clearance during pregnancy. In: Janz D (ed) Epileptology. Thieme, Stuttgart, pp 178–183
Eadie MJ, Lander CM, Tyrer JH (1977) Plasma drug level monitoring in pregnancy. Clin Pharmacokinet 2: 427–436
Forsythe GE, Malcolm MA, Moler CB (1977) Computer models for mathematical computations. Prentice Hall, Englewood Cliffs, NJ, pp 132–147
Guelen PJM (1975) Discussion, In: Schneider H, Janz D, Gardner-Thorpe C, Meinardi K, Sherwin AL (eds) Clinical pharmacology of antiepileptic drugs. Springer, Berlin Heidelberg New York pp 45–46
Gugler R, Manion CV, Azarnoff DL (1976) Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther 19: 135–142
Hayes MJ, Langman MJS, Short AH (1975) Changes in drug metabolism with increasing age. 2. phenytoin clearance and protein binding. Br J Clin Pharmacol 2: 73–79
Jusko WJ, Koup JR, Alvan G (1976) Nonlinear assessment of phenytoin bioavailability. J Pharmacokinet Biopharm 4: 327–336
Kochenour NK, Emery MG, Sawchuk RJ (1980) Phenytoin metabolism in pregnancy. Obstet Gynaecol 56: 577–582
Lander CM, Edwards VE, Eadie MJ, Tyrer JH (1977) Plasma anticonvulsant concentrations during pregnancy. Neurology (Minneapolis) 27: 128–131
Marquardt DM (1963) An algorithm for least-squares estimation of nonlinear parameters. J Soc Ind Appl Math 11: 431–441
Martis L, Levy RH (1973) Bioavailability calculations for drugs showing simultaneous first-order and capacity-limited elimination kinetics. J Pharmacokinet Biopharmaceut 1: 283–294
Metzler CM, Tong DDM (1981) Computational problems of compartment models with Michaelis-Menten-type elimination. J Pharm Sci 70: 733–737
Mygind KI, Dam M, Christiansen J (1976) Phenytoin and phenobarbitone plasma clearance during pregnancy. Acta Neurologica Scand 54: 160–166
Philbert A, Dam M (1982) Antiepileptic drug disposition during pregnancy: review of the literature. In: Janz D, Bossi L, Dam M, Helge H, Richens A, Schmidt D (eds) Epilepsy, pregnancy, and the child. Raven Press, New York, pp 109–114
Ramsay RE, Strauss RG, Wilder BJ, Willmore LJ (1978) Status epilepticus in pregnancy. Effect of phenytoin malabsorption on seizure control. Neurology (Minneapolis) 28: 85–89
Smith MT, Smith TC (1981) The unsteady model. An alternative approach to nonlinear pharmacokinetics. Eur J Clin Pharmacol 20: 387–398
About this article
Cite this article
Lander, C.M., Smith, M.T., Chalk, J.B. et al. Bioavailability and pharmacokinetics of phenytoin during pregnancy. Eur J Clin Pharmacol 27, 105–110 (1984). https://doi.org/10.1007/BF02395215
- epileptic women